Buy ARA-290 Research Peptide

What is ARA-290?

ARA-290 is a small 11-amino-acid peptide based on a tissue-protective region of erythropoietin (EPO). It is studied in animal research for its effects on nerve signaling and inflammation, without the red-blood-cell effects of full EPO.

• Based on a tissue-protective part of erythropoietin, studied for receptor-selective signaling
• Studied in animal research for its effects on inflammation
• Investigated in animal models for its effects on nerve signaling
• Acts on the innate repair receptor without the red-blood-cell signaling of full erythropoietin

For research use only. Not approved for human therapeutic use.

ARA-290 (CAS 1208243-50-8), also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective helix-B domain of erythropoietin (EPO). With the molecular formula C51H84N16O21 and a molecular weight of 1257.32 g/mol, ARA-290 is defined by the amino acid sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Structurally, Cibinetide features an N-terminal pyroglutamyl residue and was rationally designed to retain the cytoprotective signalling properties of EPO while eliminating erythropoietic activity. Produced via solid-phase peptide synthesis, ARA-290 is one of the most studied non-erythropoietic EPO derivatives in preclinical research.

ARA-290 has been investigated in preclinical tissue protection and neuroimmunology research as a compound that dissociates erythropoietin (EPO)’s cytoprotective functions from its haematopoietic activity. The innate repair receptor through which it signals is selectively upregulated in injured or inflamed tissue, providing a degree of tissue-selective targeting that has been the subject of considerable research interest. In vitro studies underpinning the design of the helix-B-derived peptides have documented that the pyroglutamate helix-B surface peptide (the structure corresponding to ARA-290) retains anti-apoptotic, cytoprotective activity, while lacking erythropoietic activity, and have attributed this cytoprotection to signalling through the EPO receptor (EPOR)/beta-common-receptor heterocomplex rather than the classical erythropoietic EPOR [1]. Preclinical rodent models of peripheral neuropathy have examined sensory signalling parameters following ARA-290 administration, documenting that ARA-290 produces long-term relief of neuropathic pain in a rat spared-nerve-injury model and characterising this effect as dependent on innate-repair-receptor engagement, coupled with suppression of the spinal microglial neuroinflammatory respons [2], making ARA-290 a reference compound in tissue-protection and neuroimmunology research examining innate-repair-receptor-mediated cytoprotective and anti-inflammatory signalling in preclinical models.

ARA-290 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925–30. ; PubMed Central PMCID: PMC2504825.PubMed PMID: 186766142Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014 Feb 16;10:13. ; PubMed Central PMCID: PMC3928087.PubMed PMID: 24529189

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

ARA-290 (CAS 1208243-50-8), also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective helix-B domain of erythropoietin (EPO). With the molecular formula C51H84N16O21 and a molecular weight of 1257.32 g/mol, ARA-290 is defined by the amino acid sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Structurally, Cibinetide features an N-terminal pyroglutamyl residue and was rationally designed to retain the cytoprotective signalling properties of EPO while eliminating erythropoietic activity. Produced via solid-phase peptide synthesis, ARA-290 is one of the most studied non-erythropoietic EPO derivatives in preclinical research.

ARA-290 has been investigated in preclinical tissue protection and neuroimmunology research as a compound that dissociates erythropoietin (EPO)’s cytoprotective functions from its haematopoietic activity. The innate repair receptor through which it signals is selectively upregulated in injured or inflamed tissue, providing a degree of tissue-selective targeting that has been the subject of considerable research interest. In vitro studies underpinning the design of the helix-B-derived peptides have documented that the pyroglutamate helix-B surface peptide (the structure corresponding to ARA-290) retains anti-apoptotic, cytoprotective activity, while lacking erythropoietic activity, and have attributed this cytoprotection to signalling through the EPO receptor (EPOR)/beta-common-receptor heterocomplex rather than the classical erythropoietic EPOR [1]. Preclinical rodent models of peripheral neuropathy have examined sensory signalling parameters following ARA-290 administration, documenting that ARA-290 produces long-term relief of neuropathic pain in a rat spared-nerve-injury model and characterising this effect as dependent on innate-repair-receptor engagement, coupled with suppression of the spinal microglial neuroinflammatory respons [2], making ARA-290 a reference compound in tissue-protection and neuroimmunology research examining innate-repair-receptor-mediated cytoprotective and anti-inflammatory signalling in preclinical models.

ARA-290 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925–30. ; PubMed Central PMCID: PMC2504825.PubMed PMID: 186766142Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014 Feb 16;10:13. ; PubMed Central PMCID: PMC3928087.PubMed PMID: 24529189

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number1195765-45-7Molecular Weight~1,163 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-ARA290-9657

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

ARA-290 (CAS 1208243-50-8), also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective helix-B domain of erythropoietin (EPO). With the molecular formula C51H84N16O21 and a molecular weight of 1257.32 g/mol, ARA-290 is defined by the amino acid sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Structurally, Cibinetide features an N-terminal pyroglutamyl residue and was rationally designed to retain the cytoprotective signalling properties of EPO while eliminating erythropoietic activity. Produced via solid-phase peptide synthesis, ARA-290 is one of the most studied non-erythropoietic EPO derivatives in preclinical research.

ARA-290 has been investigated in preclinical tissue protection and neuroimmunology research as a compound that dissociates erythropoietin (EPO)’s cytoprotective functions from its haematopoietic activity. The innate repair receptor through which it signals is selectively upregulated in injured or inflamed tissue, providing a degree of tissue-selective targeting that has been the subject of considerable research interest. In vitro studies underpinning the design of the helix-B-derived peptides have documented that the pyroglutamate helix-B surface peptide (the structure corresponding to ARA-290) retains anti-apoptotic, cytoprotective activity, while lacking erythropoietic activity, and have attributed this cytoprotection to signalling through the EPO receptor (EPOR)/beta-common-receptor heterocomplex rather than the classical erythropoietic EPOR [1]. Preclinical rodent models of peripheral neuropathy have examined sensory signalling parameters following ARA-290 administration, documenting that ARA-290 produces long-term relief of neuropathic pain in a rat spared-nerve-injury model and characterising this effect as dependent on innate-repair-receptor engagement, coupled with suppression of the spinal microglial neuroinflammatory respons [2], making ARA-290 a reference compound in tissue-protection and neuroimmunology research examining innate-repair-receptor-mediated cytoprotective and anti-inflammatory signalling in preclinical models.

ARA-290 is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925–30. ; PubMed Central PMCID: PMC2504825.PubMed PMID: 186766142Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014 Feb 16;10:13. ; PubMed Central PMCID: PMC3928087.PubMed PMID: 24529189

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number1195765-45-7Molecular Weight~1,163 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-ARA290-9657

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.